MCL1 Is Required for Maintenance of Intestinal Homeostasis and Prevention of Carcinogenesis in Mice.


Journal

Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630

Informations de publication

Date de publication:
07 2020
Historique:
received: 21 03 2019
revised: 25 02 2020
accepted: 10 03 2020
pubmed: 18 3 2020
medline: 1 4 2021
entrez: 18 3 2020
Statut: ppublish

Résumé

Intestinal epithelial homeostasis depends on a tightly regulated balance between intestinal epithelial cell (IEC) death and proliferation. While the disruption of several IEC death regulating factors result in intestinal inflammation, the loss of the anti-apoptotic BCL2 family members BCL2 and BCL2L1 has no effect on intestinal homeostasis in mice. We investigated the functions of the antiapoptotic protein MCL1, another member of the BCL2 family, in intestinal homeostasis in mice. We generated mice with IEC-specific disruption of Mcl1 (Mcl1 Mcl1 The antiapoptotic protein MCL1, a member of the BCL2 family, is required for maintenance of intestinal homeostasis and prevention of carcinogenesis in mice. Loss of MCL1 results in development of intestinal carcinomas, even under germ-free conditions, and therefore does not involve microbe-induced chronic inflammation. Mcl1

Sections du résumé

BACKGROUND & AIMS
Intestinal epithelial homeostasis depends on a tightly regulated balance between intestinal epithelial cell (IEC) death and proliferation. While the disruption of several IEC death regulating factors result in intestinal inflammation, the loss of the anti-apoptotic BCL2 family members BCL2 and BCL2L1 has no effect on intestinal homeostasis in mice. We investigated the functions of the antiapoptotic protein MCL1, another member of the BCL2 family, in intestinal homeostasis in mice.
METHODS
We generated mice with IEC-specific disruption of Mcl1 (Mcl1
RESULTS
Mcl1
CONCLUSION
The antiapoptotic protein MCL1, a member of the BCL2 family, is required for maintenance of intestinal homeostasis and prevention of carcinogenesis in mice. Loss of MCL1 results in development of intestinal carcinomas, even under germ-free conditions, and therefore does not involve microbe-induced chronic inflammation. Mcl1

Identifiants

pubmed: 32179094
pii: S0016-5085(20)30338-3
doi: 10.1053/j.gastro.2020.03.017
pmc: PMC7397524
pii:
doi:

Substances chimiques

Mcl1 protein, mouse 0
Myeloid Cell Leukemia Sequence 1 Protein 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

183-199

Subventions

Organisme : Cancer Research UK
ID : A21139
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A17196
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/J50032X/1
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Nat Rev Immunol. 2014 Mar;14(3):141-53
pubmed: 24566914
Nature. 2016 Oct 27;538(7626):477-482
pubmed: 27760111
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Onco Targets Ther. 2018 Oct 23;11:7301-7314
pubmed: 30425521
J Pathol. 2016 Jan;238(2):141-51
pubmed: 26414675
Cell. 1990 Jun 1;61(5):759-67
pubmed: 2188735
Nature. 2016 Dec 1;540(7631):129-133
pubmed: 27819682
Science. 2012 Aug 10;337(6095):730-5
pubmed: 22855427
J Immunol. 2011 Nov 15;187(10):5255-67
pubmed: 21967897
Nature. 2011 Jul 31;477(7364):330-4
pubmed: 21804564
J Pathol. 1996 Oct;180(2):152-9
pubmed: 8976873
Gastroenterology. 2003 Mar;124(3):762-77
pubmed: 12612914
Immunity. 2008 Dec 19;29(6):947-57
pubmed: 19100701
Nat Commun. 2016 Mar 09;7:10916
pubmed: 26956214
Blood. 2015 Jul 16;126(3):363-72
pubmed: 26045609
Nat Commun. 2019 Jan 23;10(1):397
pubmed: 30674894
Gut. 2013 Jul;62(7):1062-71
pubmed: 22689519
Nat Rev Gastroenterol Hepatol. 2017 Apr;14(4):218-229
pubmed: 28174420
Cell Death Dis. 2016 Aug 18;7(8):e2342
pubmed: 27537525
Nature. 2011 Sep 14;477(7364):335-9
pubmed: 21921917
Nature. 2012 Nov 8;491(7423):254-8
pubmed: 23034650
Nature. 2014 Sep 4;513(7516):95-9
pubmed: 25186904
Cell. 2018 Nov 1;175(4):1156-1167.e15
pubmed: 30270040
Semin Immunol. 2007 Apr;19(2):59-69
pubmed: 17118672
Trends Cell Biol. 2013 Jan;23(1):22-9
pubmed: 23026029
Nature. 2014 Sep 4;513(7516):90-4
pubmed: 25132550
Cancer Cell. 2018 Apr 9;33(4):721-735.e8
pubmed: 29622466
J Clin Invest. 2018 Jan 2;128(1):500-516
pubmed: 29227281
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Annu Rev Physiol. 2009;71:241-60
pubmed: 18808327
Nature. 2016 Dec 1;540(7631):124-128
pubmed: 27819681
Nat Rev Cancer. 2013 Jul;13(7):455-65
pubmed: 23783119
Genes Dev. 2004 Jun 15;18(12):1385-90
pubmed: 15198980
Pharmacol Ther. 2019 Jun;198:59-67
pubmed: 30790641
Nat Commun. 2018 Dec 17;9(1):5341
pubmed: 30559424
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Mol Cell Biol. 2017 Jan 19;37(3):
pubmed: 27821478
Cancer Cell. 2017 Sep 11;32(3):342-359.e10
pubmed: 28898696
Gastroenterology. 2007 Feb;132(2):628-32
pubmed: 17320548
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Nature. 2015 Jan 15;517(7534):293-301
pubmed: 25592534
Science. 2001 Dec 7;294(5549):2155-8
pubmed: 11739954
Nat Cell Biol. 2014 Jan;16(1):2-9
pubmed: 24366029
J Clin Pathol. 2018 Dec;71(12):1033-1040
pubmed: 30275102
Hepatology. 2010 Apr;51(4):1226-36
pubmed: 20099303
Science. 2005 Feb 18;307(5712):1101-4
pubmed: 15718471

Auteurs

Marc E Healy (ME)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.

Yannick Boege (Y)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Michael C Hodder (MC)

Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow, UK; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow, UK. Electronic address: achim.weber@usz.ch.

Friederike Böhm (F)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Mohsen Malehmir (M)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Anna-Lena Scherr (AL)

National Center for Tumor Diseases, Department of Medical Oncology and Heidelberg University Hospital, Internal Medicine VI, Heidelberg, Germany.

Jasna Jetzer (J)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Lap Kwan Chan (LK)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Rossella Parrotta (R)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Kurt Jacobs (K)

Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.

Laure-Alix Clerbaux (LA)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.

Susanne Kreutzer (S)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Andrew Campbell (A)

Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow, UK.

Ella Gilchrist (E)

Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow, UK.

Kathryn Gilroy (K)

Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow, UK.

Ann-Katrin Rodewald (AK)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Hanna Honcharova-Biletska (H)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Roman Schimmer (R)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Karelia Vélez (K)

Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.

Simone Büeler (S)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.

Patrizia Cammareri (P)

Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow, UK.

Gabriela Kalna (G)

Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow, UK.

Anna S Wenning (AS)

Maurice Müller Laboratories (DKF), Universitätsklinik für Viszerale Chirurgie und Medizin Inselspital, University of Bern, Bern, Switzerland.

Kathy D McCoy (KD)

Maurice Müller Laboratories (DKF), Universitätsklinik für Viszerale Chirurgie und Medizin Inselspital, University of Bern, Bern, Switzerland; Department of Physiology and Pharmacology and Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Mercedes Gomez de Agüero (M)

Maurice Müller Laboratories (DKF), Universitätsklinik für Viszerale Chirurgie und Medizin Inselspital, University of Bern, Bern, Switzerland.

Henning Schulze-Bergkamen (H)

National Center for Tumor Diseases, Department of Medical Oncology and Heidelberg University Hospital, Internal Medicine VI, Heidelberg, Germany.

Christoph S N Klose (CSN)

Institute of Microbiology, Infectious Diseases and Immunology, Charité - Universitätsmedizin Berlin, Germany.

Kristian Unger (K)

Research Unit of Radiation Cytogenetics, Helmholtz Zentrum München, Neuherberg Germany.

Andrew J Macpherson (AJ)

Maurice Müller Laboratories (DKF), Universitätsklinik für Viszerale Chirurgie und Medizin Inselspital, University of Bern, Bern, Switzerland.

Andreas E Moor (AE)

Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland.

Bruno Köhler (B)

National Center for Tumor Diseases, Department of Medical Oncology and Heidelberg University Hospital, Internal Medicine VI, Heidelberg, Germany.

Owen J Sansom (OJ)

Cancer Research UK Beatson Institute, Garscube Estate, Bearsden, Glasgow, UK; Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Glasgow, UK. Electronic address: o.sansom@beatson.gla.ac.uk.

Mathias Heikenwälder (M)

Division of Chronic Inflammation and Cancer, Deutsches Krebs-Forschungszentrum (DKFZ), Heidelberg, Germany. Electronic address: m.heikenwaelder@dkfz.de.

Achim Weber (A)

Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland; Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland. Electronic address: achim.weber@usz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH